Clindamycin as Antimicrobial Treatment for Streptococcus Spp. PeRiprosthetic Infection
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 260
- 试验地点
- 1
- 主要终点
- Therapeutic success of the medical-surgical strategy
研究概览
简要总结
Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained.
The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections.
The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (aged 18 years or older) at the time of surgery for infection
- •Probable or proven periprosthetic infection with Streptococcus spp. according to EBJIS diagnostic criteria
- •Patient operated on in one of the associated centers between 2013 and 2024
排除标准
- •Patient who underwent joint resection or amputation
- •Patient who was treated with suppressive antibiotic therapy (defined as antibiotic treatment lasting more than 6 months) which was decided upon prior to surgery
结局指标
主要结局
Therapeutic success of the medical-surgical strategy
时间窗: One year after the end of antibiotic treatment
Therapeutic success of the medical-surgical strategy defined as: patient showing no clinical signs of infection, no need for repeat surgery one year after the end of antibiotic treatment, and no repeat antibiotic treatment.
次要结局
未报告次要终点